Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | RXRG | P48443 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870144 | 0.85 | RXRA (0.56) | EPHX2PTGS2ALOX5AKR1C3RXRA | |
| SCHEMBL6464441 | 0.85 | ALOX5 (0.59) | EPHX2PTGS2ALOX5AKR1C3CYP2C9 | |
| SCHEMBL3862609 | 0.84 | PTGS2 (0.54) | EPHX2PTGS2ALOX5AKR1C3CYP2C9 | |
| SCHEMBL839547 | 0.81 | RXRA (0.67) | EPHX2PTGS2ALOX5RXRARXRB | |
| SCHEMBL3864744 | 0.79 | PTGS2 (0.61) | EPHX2PTGS2ALOX5CYP2C9PTGS1 | |
| SCHEMBL8954103 | 0.79 | PTGS2 (0.81) | PTGS2ALOX5CYP2C9PTGS1 | |
| SCHEMBL3864811 | 0.78 | CHRNA7 (0.65) | EPHX2PTGS2CYP2C9PTGS1CHRNA7 | |
| SCHEMBL15560871 | 0.78 | RXRA (0.62) | EPHX2PTGS2ALOX5AKR1C3RXRA | |
| SCHEMBL8421124 | 0.78 | PTGS2 (0.89) | PTGS2RXRACYP2C9PTGS1 | |
| SCHEMBL9941416 | 0.77 | ALOX5 (0.81) | EPHX2PTGS2ALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442802-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-28 | — | — | US | claimed |
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7442802-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7087630-B2 | Cyclooxygenase 2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | EPHX2 64/4885PTGS2 1/4885ALOX5 20/4885 |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | EPHX2 64/4885PTGS2 1/4885ALOX5 20/4885 |
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTGS2, PTGIS, PTGES2 | EPHX2 64/4885PTGS2 1/4885ALOX5 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.